Interesting Stocks: ArcelorMittal SA (NYSE:MT), OXiGENE (NASDAQ:OXGN), Morgan Stanley (NYSE:MS), Pieris Pharmaceuticals (NASDAQ:PIRS)

Halliburton Company (NYSE:HAL) ended the last trading day at $34.48. Company weekly volatility is calculated as 2.39% and price to cash ratio as 13.12. Halliburton Company (NYSE:HAL) showed a weekly performance of -1.91%.

On 22 December, Halliburton Company (NYSE:HAL) announced that, it will extend its merger agreement with Baker Hughes (BHI – Get Report)through the end of April was favorable news for the $35 billion deal. The announcement means the merger still stands a fair shot at getting antitrust approval from the U.S. Department of Justice.

On 04 January, ArcelorMittal SA (ADR) (NYSE:MT) shares moved down -4.27% and was closed at $4.04. MT EPS growth in last 5 year was -43.40%. ArcelorMittal SA (ADR) (NYSE:MT) year to date (YTD) performance is -4.27%.

ArcelorMittal SA (ADR) (NYSE:MT) announces that Lou Schorsch, 66, senior executive vice president, member of the Group Management Board and CEO of ArcelorMittal Americas will retire from the company, effective end of February 2016.

OXiGENE, Inc. (NASDAQ:OXGN) shares moved down -1.96% in last trading session and ended the day at $0.75. OXGN has a return on assets of -37.50%. OXiGENE, Inc. (NASDAQ:OXGN) quarterly performance is -17.22%.

On 3 January, OXiGENE, Inc. (NASDAQ:OXGN) said that, it provides an overview of the OXiGENE, Inc.’s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of OXiGENE, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Morgan Stanley (NYSE:MS) shares decreased -1.04% in last trading session and ended the day at $31.48. MS Gross Margin is 86.90% and its has a return on assets of 0.40%. Morgan Stanley (NYSE:MS) quarterly performance is 0.63%.

On 31 December, Morgan Stanley (NYSE:MS) raised its estimates on AAC TECHNOLOGIES H USD0.01 AACAF to a $65.00 price target based on Apple Inc. expectations.

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) caters to the Healthcare space. Its weekly performance is -0.43%. On the last day of trading company shares ended up at $2.29. Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) distance from 50-day simple moving average (SMA50) is -3.53%.

Oppenheimer reaffirmed their buy rating on shares of Pieris Pharmaceuticals Inc (NASDAQ:PIRS) in a research report published on Tuesday morning,AnalystRatingsNetwork.com reports. Oppenheimer currently has a $10.00 target price on the stock, up from their previous target price of $8.00.